Literature DB >> 36209179

The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.

Olivia T Van Gerwen1, Ibrahim Yigit2, Kaylee B Crockett3, Bulent Turan4,5.   

Abstract

Despite efficacy in HIV prevention, Pre-exposure Prophylaxis (PrEP) is underutilized in the US, especially among populations at highest risk. PrEP-related stigma may play a role. We developed measures of PrEP-related stigma dimensions and PrEP adherence. We administered them to current PrEP users. We hypothesized that PrEP-related stigma would negatively impact PrEP adherence. Questionnaire measures were developed using data from previous qualitative work and existing validated HIV-related stigma measures. The resultant survey was administered to current PrEP users from two Birmingham, Alabama PrEP clinics. Plasma tenofovir disoproxil fumarate levels were collected to measure PrEP adherence. Exploratory factor analyses were performed to determine the factor structure of each PrEP-related stigma dimension (internalized, perceived, experienced, anticipated, disclosure concerns). Separate binary logistic (or linear) regressions were performed to assess associations between PrEP-related stigma dimensions and adherence (treatment adherence self-efficacy, self-reported adherence, and plasma tenofovir levels), adjusting for education, race, and time on PrEP. In 2018, 100 participants completed the survey, with 91 identifying as male and 66 as white. Only internalized stigma was associated with lower self-reported PrEP adherence. Exploratory mediation analyses suggested that the association between all stigma dimensions and self-reported PrEP adherence is mediated by PrEP adherence self-efficacy. No associations were found between any PrEP-related stigma measures and plasma tenofovir levels. Internalized PrEP stigma may reduce PrEP adherence, possibly by reducing PrEP adherence self-efficacy among experienced PrEP users. Further investigation of how stigma dimensions affect PrEP adherence in populations at risk for HIV may shed light on drivers of PrEP underutilization.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adherence; HIV pre-exposure prophylaxis; PrEP; Stigma

Year:  2022        PMID: 36209179     DOI: 10.1007/s10461-022-03883-3

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  44 in total

Review 1.  How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores".

Authors:  Sarah K Calabrese; Kristen Underhill
Journal:  Am J Public Health       Date:  2015-08-13       Impact factor: 9.308

2.  Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Authors:  Kenneth H Mayer; Jean-Michel Molina; Melanie A Thompson; Peter L Anderson; Karam C Mounzer; Joss J De Wet; Edwin DeJesus; Heiko Jessen; Robert M Grant; Peter J Ruane; Pamela Wong; Ramin Ebrahimi; Lijie Zhong; Anita Mathias; Christian Callebaut; Sean E Collins; Moupali Das; Scott McCallister; Diana M Brainard; Cynthia Brinson; Amanda Clarke; Pep Coll; Frank A Post; C Bradley Hare
Journal:  Lancet       Date:  2020-07-25       Impact factor: 79.321

3.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

Review 4.  PrEP Stigma: Implicit and Explicit Drivers of Disparity.

Authors:  Sarit A Golub
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

5.  Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.

Authors:  Pamela M Murnane; Connie Celum; Nelly Mugo; James D Campbell; Deborah Donnell; Elizabeth Bukusi; Andrew Mujugira; Jordan Tappero; Erin M Kahle; Katherine K Thomas; Jared M Baeten
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

6.  The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.

Authors:  Aaron J Siegler; Farah Mouhanna; Robertino Mera Giler; Kevin Weiss; Elizabeth Pembleton; Jodie Guest; Jeb Jones; Amanda Castel; Howa Yeung; Michael Kramer; Scott McCallister; Patrick S Sullivan
Journal:  Ann Epidemiol       Date:  2018-06-15       Impact factor: 3.797

7.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

8.  Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.

Authors:  Lisa A Grohskopf; Kata L Chillag; Roman Gvetadze; Albert Y Liu; Melanie Thompson; Kenneth H Mayer; Brandi M Collins; Sonal R Pathak; Brandon Oʼhara; Marta L Ackers; Charles E Rose; Robert M Grant; Lynn A Paxton; Susan P Buchbinder
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

9.  High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.

Authors:  Elisabeth Maria Van der Elst; Judie Mbogua; Don Operario; Gaudensia Mutua; Caroline Kuo; Peter Mugo; Jennifer Kanungi; Sagri Singh; Jessica Haberer; Frances Priddy; Eduard Joachim Sanders
Journal:  AIDS Behav       Date:  2013-07

10.  Structural Barriers to Pre-exposure Prophylaxis Use Among Young Sexual Minority Men: The P18 Cohort Study.

Authors:  Jessica Jaiswal; Marybec Griffin; Stuart N Singer; Richard E Greene; Ingrid Lizette Zambrano Acosta; Saara K Kaudeyr; Farzana Kapadia; Perry N Halkitis
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.